‌2018‌

• Develop medical preparations that best suit the patient's condition, so as to achieve the best personalized treatment for patients.

• Achieve rapid combination of existing targeted molecules and existing therapeutic preparations ‌via our proprietary polyethylene glycol (PEG) linker technology‌, which enables rapid development of a drug library of thousands of targeted molecule-guided therapeutic preparations for integration with clinical treatment.

• The drug delivery intermediates developed by Wuhan Boren Kairui Pharmaceutical Co., Ltd. utilize the most advanced existing nanoparticle targeting technology.

• Most of the current targeted drug delivery technologies focus on developing new biological targeting molecules to guide existing drugs.

‌2015‌

• Develop and produce PEG linker-modified nanoliposome formulation materials and lipophilic nanoparticle formulation materials, providing reliable materials and technical support for the urgently needed domestic and international targeted drug delivery industry.

• Mass-produce internationally popular PEG linker products.

• Develop medical preparations that best suit the patient's condition, so as to achieve the best personalized treatment for patients.

‌2013‌

• Wuhan Boren Kairui Pharmaceutical Co., Ltd. was founded in September 2013.

• Mass-produce internationally popular PEG linker products.

• Develop medical preparations that best suit the patient's condition, so as to achieve the best personalized treatment for patients.

• Achieve rapid combination of existing targeted molecules and existing therapeutic preparations via our polyethylene glycol (PEG) linker technology, which enables rapid development of a drug library of thousands of targeted molecule-guided therapeutic preparations for integration with clinical treatment.